Categories
Add Resources - Research & Development

Using digital tools data science to strengthen COVID-19 management – India Case Study

India’s digital ecosystem for COVID-19 management has centred around Aarogya Setu – Sanskrit for “Bridge to Health” – a public-facing mobile application designed in response to the pandemic. 

Software engineers, epidemiologists, statisticians, social scientists and legal experts from across India started to work with the Indian government to develop a digital response to the pandemic in March 2020.

The resulting systems, new digital tools as well as adapted existing tools, aimed to help test-trace-isolate (TTI) programme activities, predict emerging hotspots and identify high-risk individuals in need of targeted testing. 

This case study examines how India leveraged these digital solutions in their COVID-19 response.

India’s numbers

First confirmed COVID-19 case: 28 January 2020.

1 March 2021:  11-million cumulative cases detected from 227-million tests. 

15 March 2021: 2,19,262 active cases, a cumulative recovery rate of 96.7% and death rate of 1.4%.

The digital backbone of Aarogya Setu 

Aarogya Setu, the backbone of India’s COVID-19 management strategy, is a mobile application launched on 2 April 2020. By November 2020, it had 170 million registered users, or 13% of the country’s population.

Users download the app free and register using their mobile number, following which a de-identified identification (DID) is generated to enable anonymised transfer of their data in the system. It captures two key sets of data:

  • Self-reported symptoms – for case management and hotspot mapping 
  • Location (via Bluetooth) for contact alerts

Aarogya Setu then scores user risk based on exposure to confirmed cases to determine who is at high risk of infection and should be prioritised for testing. Based on this, follow-up actions are recommended: Caution, Quarantine or Test.

Information on high-risk individuals is also transmitted to the Ayushman Bharat call centre, which follows up with them by phone to support linkage to testing and care.

Within the first eight weeks of the app’s introduction, more than 900 000 users identified through the algorithm had been contacted. 

India’s response also leveraged the pre-existing electronic infrastructure of Ayushman Bharat, the National Health Authority (NHA) scheme to provide free healthcare to 500-million citizens. 

The IT-enabled Integrated Hotspot Analysis System (ITIHAS) uses syndromic data submitted by Aarogya Setu users to map future hotspots. This in turn informs targeted testing strategies.

ITIHAS also generates hotspot predictions using the historic location data, based on cell phone tower signals, of confirmed positives diagnosed in the Indian Council of Medical Research (ICMR)’s network of approved labs. 


Digital tools: the benefits 

Digital health solutions can help address high-priority gaps, particularly in India, which has high overall digital maturity and a rapidly evolving digital health landscape. 

Digital solutions tailored to support the integration and/or bundling of tests provide an opportunity to identify at-risk patients earlier and intervene faster. 

Practical ways to scale

India’s government has established a positive and enabling environment for ICT intervention in health. 

In August 2020 the country launched the National Digital Health Mission, in which every Indian was due to receive an electronic health account in the form of a mobile application.

Challenges

Despite its digital maturity, India’s health system is underfunded, with government healthcare spending only 0.96% of its GDP. 

This is lower than spend in other low- and middle-income countries (1.3%), and BRIC countries (3.0%). It contributes to a lack of adequate public health services, especially in rural areas. 

India’s population relies heavily on private health providers, in the face of an under-resourced and unregulated health system, skilled staff shortages and disparate management systems.  

KEY INSIGHTS

India has an increasingly low-cost and fast digital infrastructure, with high mobile phone penetration and growing smartphone penetration. This has enabled extensive use of the Aarogya Setu mobile app.

As mobile penetration and ICT literacy in India is growing rapidly, scale-up of digital health tools will be necessary to optimise the nation’s limited resources, bridge inequity in healthcare access and strengthen the availability of quality diagnostics. 

Categories
Featured Work - Quality Assurance & Policy

WHO: In vitro diagnostics for COVID-19

Safe and effective in vitro diagnostics (IVDs) are a critical component of an overall strategy to control the COVID-19 pandemic.

WHO prequalification of in vitro diagnostics (IVDs) provides a valuable service to manufacturers and regulators in both quality assurance and product selection.

It has developed an Emergency Use Listing (EUL) procedure to hasten the availability of IVDs in public health emergencies such as COVID-19.

WHO reviews all documentation submitted for EUL and checks the evidence on a product’s safety, quality and performance. This procedure helps agencies and Member States decide on which IVD is suitable for their use. 

The IVD part of the WHO prequalification website also provides key prequalification outputs as well as detailed information about submission of IVDs.

·       Read more here

Categories
Add Resources - Quality Assurance & Policy

WHO interim guidance: antigen-detection in the diagnosis of SARS-CoV-2 infection

This is an interim guidance published by the World Health Organization on how to select rapid antigen tests and when and where to use them.

Rapid antigen tests for SARS-CoV-2 are less expensive and faster. They should be used for primary case detection in symptomatic individuals and asymptomatic individuals who are at high risk of COVID-19, such as health workers. 

The tests should also be used for contact tracing, conducting outbreak investigations, and to monitor trends of disease incidence in communities. 

There are some variations in test performance, but these tests are very much suitable in track, trace, and isolate programmes aimed at interrupting community transmission.

Categories
Add Resources - Quality Assurance & Policy

WHO interim guidance: Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities

In June 2021, the World Health Organization issued recommendations for SARS-CoV-2 national testing strategies.

At the time, the deadly Delta variant was the dominant variant globally.

WHO recommendations highlight the importance of diagnostic testing for SARS-CoV-2 as a critical component for both preventing the spread of the virus and controlling outbreaks. 

It advised that countries should have testing strategies in place that are context specific and that testing must be connected to other public health strategies like tracking, tracing, and treatment.

WHO’s list of who should be tested

  • Everyone with symptoms meeting the case definition for COVID-19, regardless of vaccination status or prior infection. 
  • Symptomatic individuals must be tested first and if there are not enough tests, those who are at high risk of severe disease must be tested first. 
  • Others for whom testing must be prioritized include health workers, hospitalized patients, and those who first showed symptoms in congregate settings.

Asymptomatic individuals should be tested if they were in close contact with  patients with a confirmed SARS-CoV-2 infection, health workers or long-term care workers.

What tests must be used?

PCR tests remain the gold standard. 

High-quality antigen tests can be used to scale up testing programmes fast.

Categories
Featured Work - Quality Assurance & Policy

WHO interim guidance: Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing 

In March 2022, the World Health Organization published its first guide to self-testing for COVID-19 using rapid antigen tests.

“The goal is to contribute to the effective management of COVID-19 as a public health problem,” their guidelines read.

The document emphasizes  that this option must be offered in addition to professionally administered testing.

WHO further explains that there is evidence showing users can use self-tests in a reliable and accurate manner, and that it is both acceptable and feasible to use the tests.

An explanation of when self-testing will be appropriate must be provided, as must complete instructions tailored for country specific contexts.

Clear messaging is also needed on what to do with the results of a test and what individual responsibilities will be.

Other recommendations include:

  • COVID-19 self-test kits should meet the existing World Health Organization (WHO) standards.
  • Self-tests should be accepted for screening and diagnostic purposes.
  • If positive, a self-test should, if appropriate in a country-specific context, be sufficient to link a positive-tested patient with clinical care and therapeutics. 
Categories
Add Resources - Quality Assurance & Policy

SARS-CoV-2 antigen-detecting rapid diagnostic tests: An implementation guide

This guide, produced by FIND and the World Health Organization, provides information on implementing diagnostic programs using rapid antigen tests. 

It shows how rapid antigen testing can be implemented to support individual case management, contact tracing, surveillance and outbreak investigations.

The guide stresses the use of strict testing protocols and clear communication, and the need to protect healthcare workers against transmission. 

It outlines the different types of available testing  and where rapid antigen testing fits in. Rapid antigen tests are used to find a protein the body produces in response to an infection with the SARS-CoV-2 virus.

It produces fast results and is easy to use in low-resource settings where laboratories are unavailable. 

The guide provides step-by-step instructions on the use of these tests and how best to communicate and follow up on patients after a test result is obtained. 

It also explains the best practice of testing within 5 to 7 days of the onset of symptoms. 

While rapid tests are easy to use in most instances, the guide lists where they should not be used. 

This includes testing patients without symptoms unless they are a close contact of a confirmed case; where there are no appropriate infection control measures in place; where test results will not influence the treatment of the patients and for screening at points of entry.

The use of rapid antigen tests is also not advised  prior to elective surgery or blood donation.

Categories
Featured Work - Manufacturing

COVID-19 diagnostics: preserving manufacturing capacity for future pandemics

Manufacturing capacity for diagnostics increased at a rapid rate during the COVID-19 pandemic. It is estimated to have grown by 200% since the onset of the pandemic. Sustaining this expanded capacity over the long term will require coordinated strategies to ensure the progress made in recent years is not lost. 


The authors of this commentary piece, representing the ACT-A Diagnostics Partnership, suggest strategies which could be implemented to preserve manufacturing capacity in the face of future pandemic threats.

Categories
Featured Work - Awareness & Advocacy

FIND and Unitaid invest US$2 million to support advocacy for COVID-19 test-and-treat approaches in low- and middle-income countries

FIND, the global alliance for diagnostics and Unitaid are investing US$2 million in a coordinated advocacy programme spanning 19 low- and middle-income countries (LMICs) designed to boost access and uptake of COVID-19 tests and treatments. A total of 21 organizations with a diverse range of healthcare expertise have been selected from more than 300 applicants, following a request for proposals (RFP) and competitive selection process that included assessment by a panel of independent reviewers. Criteria for funding included previous public health advocacy experience and expected impact of test-and-treat advocacy in the targeted region.

Projects range in duration from 6 to 18 months, and will raise awareness of COVID-19 testing and treatment among the public, key opinion leaders, and specific high-risk and vulnerable groups. Partners include (listed alphabetically by country): Mhair Educational, Health and Human Rights Organization (Afghanistan), Family Planning Association of Bangladesh (Bangladesh), IMAG Communication (Burkina Faso), Maison des Associations de lutte contre le Sida (Burkina Faso), Health Poverty Action Cambodia (Cambodia), Caritas Développement Mbujimayi (Democratic Republic of the Congo), TB Alert India (India), Pi Consulting (India), Kenya AIDS NGOs Consortium (Kenya), Health Poverty Action Laos (Laos), Caritas Lesotho (Lesotho), ESTAMOS (Mozambique), REDTRANS (Nicaragua), Shifa Foundation (Pakistan), Media for Deaf Rwanda (Rwanda), South Sudan Community Change Agency (South Sudan), Sikika (Tanzania), Université Mahmoud El Materi (Tunisia), HEPS (Uganda), Zambia Interfaith Working Group (Zambia), Pan-African Treatment Access Movement (Zimbabwe).

Categories
Add Resources - Awareness & Advocacy

Information Note for CSOs on COVID-19 Testing 

As vaccines are rolled out globally, testing remains a critical way to manage and monitor COVID-19 outbreaks. Without testing, we cannot track or contain the spread of the virus, address urgent clinical needs, refer patients for treatment, test the efficacy of vaccination, and detect the emergence of new variants. 

A combination of different types of tests are needed to facilitate patient management and public health planning for effective control of COVID-19. The Global Fund encourages countries to include all appropriate types of tests when developing their COVID-19 Response Mechanism (C19 RM) funding proposals. 

This information note provides a breakdown of the different types of COVID-19 tests available at the time. 

Categories
Add Resources - Awareness & Advocacy

FIND and partners from the Access to COVID-19 Tools (ACT) Accelerator Diagnostics Pillar call on the G20 and G7 to prioritize diagnostics in its pandemic preparedness and response plans

The COVID-19 pandemic has shown that access to timely, accurate diagnostics is fundamental to effective healthcare. The Access to COVID-19 Tools (ACT) Accelerator is a unique but time-limited partnership that was set up to respond to the acute phase of the COVID-19 pandemic.

As world leaders including the G7 and G20 are aligning efforts for future pandemic preparedness and creating a G7 Pact for Pandemic Readiness, FIND and ACT-Accelerator Diagnostics Pillar partners call on both G7 and G20 to reaffirm commitments relating to diagnostics as part of the 100 Days Mission put forward during the UK G7 Presidency in 2021.